Aridis Pharmaceuticals, Inc. (ARDS)
| Market Cap | 5.33K -50.0% |
| Revenue (ttm) | 22.36M +680.4% |
| Net Income | -1.14M |
| EPS | -0.04 |
| Shares Out | 53.32M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 374,480 |
| Open | 0.0002 |
| Previous Close | 0.0002 |
| Day's Range | 0.0001 - 0.0002 |
| 52-Week Range | 0.000001 - 0.0500 |
| Beta | 3,968.26 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Aridis Pharmaceuticals
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. ... [Read more]
News
Aridis Pharmaceuticals continuing to explore ‘multiple paths to monetize’ assets
Aridis Pharmaceuticals (ARDS) announced a corporate update on recent developments. The company said, “The Company continues to diligently explore multiple paths to monetize its assets amidst a protrac...
Aridis Provides Corporate Update
LOS GATOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent dev...
Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024
LOS GATOS, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC QB: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies...
Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update
Received two grant awards from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health
Aridis Pharmaceuticals price target lowered to $2 from $10 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Aridis Pharmaceuticals to $2 from $10 and keeps a Buy rating on the shares. The company’s near-term challenge is funding a Phase…
Aridis Pharmaceuticals prices 10M shares at 20c in offering
Aridis Pharmaceuticals announced the pricing of an offering of 10,000,000 shares of the Company’s common stock and accompanying warrants to purchase up to 10,000,000 shares of common stock at a…
Aridis Pharmaceuticals Announces $2 Million Offering
Los Gatos, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies fo...
Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301
LOS GATOS, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the European Medicines Agency (EMA) on the Company's proposed si...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Aridis Pharmaceuticals (ARDS), 774% surge in interest Eye...
Aridis Pharmaceuticals’ AR-301 receives FDA’s QIDP designation
Aridis Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has granted Qualified Infectious Disease Product, QIDP, Designation under the Generating Antibiotic Incentives Now, GA...
Aridis' AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA's Qualified Infectious Diseases Product (QIDP) Designation
LOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies...
Aridis Pharmaceuticals and Rail Vision Interviews to Air on Bloomberg TV on the RedChip Money Report(R)
ORLANDO, FL / ACCESSWIRE / June 30, 2023 / RedChip Companies will air interviews with Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) and Rail Vision Ltd. (NASDAQ:RVSN) on The RedChip Money Report® on Bloo...
Aridis Pharmaceuticals’ AR-301 is eligible for consideration under FDA’s LPAD
Aridis Pharmaceuticals announced that its AR-301 clinical program has been deemed eligible for consideration under the U.S. Food and Drug Administration’s, FDA, Limited Population Pathway for Antibact...
Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update
LOS GATOS, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies...
Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Q
LOS GATOS, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, announced today that it received a notice (the...
Aridis Pharmaceuticals receives Nasdaq notice on late filing of Form 10-K
Aridis Pharmaceuticals announced that it received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC on April 19, 2023 indicating that the company is not currently…
Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-K
LOS GATOS, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, announced today that it received a notice (t...
Aridis Pharmaceuticals announces $2.28M registered direct offering
Aridis Pharmaceuticals announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 6M shares of the company’s common stock at a purchase…
Aridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common Stock
Los Gatos, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company, today announced that it has entered into a definitive agreement for the ...
Aridis Skyrockets on Impressive Data In Cystic Fibrosis
Shares of biopharmaceutical company Aridis Pharmaceuticals (NASDAQ:ARDS) are soaring higher today after the company announced preliminary top-line results from a Phase 2a trial evaluating AR-501 for t...
Interviews with Rail Vision, Aridis Pharmaceuticals, and Digital Ally to Air on Bloomberg U.S. on the RedChip Money Report(R)
ORLANDO, FL / ACCESSWIRE / February 17, 2023 / RedChip Companies will air new interviews with Rail Vision Ltd. (Nasdaq:RVSN), Aridis Pharmaceuticals, Inc. (Nasdaq:ARDS), and Digital Ally, Inc. (NASDAQ...
Aridis Pharmaceuticals price target lowered to $10 from $19 at H.C. Wainwright
H.C. Wainwright analyst Vernon Bernardino lowered the firm’s price target on Aridis Pharmaceuticals to $10 from $19 and keeps a Buy rating on the shares. The analyst factored in the…
Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)
LOS GATOS, Calif, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced top-line results from the AR-301-002 Phase 3 study, which evaluated the superiority of a...
New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Update
AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in CF patients
Aridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301 During Corporate Update Call on January 25
Los Gatos, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a biopharmaceutical company focused on the discovery and development of novel anti-infective therapie...